Beam Therapeutics Inc.
NASDAQ:BEAMBiotechnology
+$0.48 today
- Market cap
- $2.17B
- Beta
- 2.20
- P/E (TTM)
- -52.3
- EPS (TTM)
- -$0.63
Volume 4.86M
Average 2.11M
BEAM Total Current Assets
All assets expected to be converted to cash or used up within one year.
Beam Therapeutics Inc.NASDAQ: BEAM
Total Current Assets · Q2 FY2026 · quarter ended Jun 2026
Total current assets broadly unchanged from a year ago
Total current assets stood at $1.18B at the end of Q2 FY2026, up 0.3% from a year earlier and down 7.0% from the prior quarter. Over 3 fiscal years it compounded at +5.1% a year.
Context
- Total current assets amounted to 85.0% of total assets at the end of Q2 FY2026, up 0.5 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +0.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.27B USD
- Year-over-year change
- +44.5%
- 4-year CAGR
- -0.1%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.27B | +44.5% |
| FY2024 | 2024-12-31 | 878.15M | -27.5% |
| FY2023 | 2023-12-31 | 1.21B | +10.8% |
| FY2022 | 2022-12-31 | 1.09B | -14.1% |
| FY2021 | 2021-12-31 | 1.27B | — |
Total Current Assets vs competitors
How BEAM compares with its peers on the latest reported figures
- BEAM's Jun 2026 total current assets of $1.18B is the 2nd highest of the 9 companies compared; the peer median is $192.04M.
- Its year-over-year change of +0.3% is the 3rd highest of 9, against a peer median of -20.1%.
- Total current assets amounts to 85.0% of total assets for BEAM, versus a peer median of 73.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $2.27B | +17.8% | +2.3% | 88.9% | |
| Jun 2026 | $1.18B | +0.3% | +5.1% | 85.0% | |
| Mar 2026 | $466.45M | -15.4% | -24.3% | 61.5% | |
| Mar 2026 | $273.29M | -6.3% | -21.3% | 69.0% | |
| Mar 2026 | $204.55M | -24.7% | +18.0% | 70.7% | |
| Mar 2026 | $179.53M | -27.7% | -25.4% | 63.0% | |
| Mar 2026 | $128.07M | -43.0% | -22.8% | 85.8% | |
| Mar 2026 | $122.38M | -43.7% | -17.7% | 82.1% | |
| Mar 2026 | $108.69M | +32.4% | -15.8% | 75.5% | |
| Peer median (excluding BEAM) | $192.04M | -20.1% | -19.5% | 73.1% | |
Competitors are the stored peer set for BEAM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 559.99M | 232.77M | 435.9M | 281.97M | 294.94M |
| Short-term Investments | 405.65M | 845.37M | 753.98M | 568.77M | 950.27M |
| Net Receivables | 300M | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 14.76M | 21.17M | 27.41M | 0 |
| Total Current Assets | 1.27B | 1.09B | 1.21B | 878.15M | 1.27B |
| Property, Plant & Equipment (Net) | 186.98M | 234.13M | 237.81M | 216.28M | 205.18M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 6.68M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 14.47M | 14.69M | 10.87M | 9.4M | 634K |
| Total Non-current Assets | 201.45M | 248.82M | 248.67M | 225.68M | 212.49M |
| Total Assets | 1.47B | 1.34B | 1.46B | 1.1B | 1.48B |
| Account Payables | 7.47M | 9.03M | 1.62M | 3.87M | 10.23M |
| Short-term Debt | 2.29M | 0 | 0 | 0 | 14.36M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 86.27M | 135.97M | 68.71M | 108.86M | 6.66M |
| Other Current Liabilities | 60.83M | 49.68M | 100.69M | 19.74M | 36.34M |
| Total Current Liabilities | 213.44M | 223.6M | 205.57M | 182.07M | 96.94M |
| Long-term Debt | 3.01M | 0 | 0 | 0 | 139.76M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 262.3M | 202.18M | 109.89M | 33.22M | 0 |
| Other Non-current Liabilities | 34.16M | 13.84M | 3.02M | 7.04M | (133.63M) |
| Total Non-current Liabilities | 434.28M | 384.65M | 272.82M | 188.21M | 145.88M |
| Total Liabilities | 647.72M | 608.24M | 478.39M | 370.28M | 242.82M |
| Common Stock | 684K | 712K | 816K | 836K | 1.02M |
| Retained Earnings | (768.27M) | (1.06B) | (1.19B) | (1.57B) | (1.64B) |
| Accumulated OCI | (50K) | (2.43M) | 604K | 679K | 1.11M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 826.74M | 733.47M | 981.33M | 733.55M | 1.24B |
| Total Debt | 147.64M | 179.01M | 172.69M | 161.43M | 293.88M |
| Net Debt | (412.35M) | (53.76M) | (263.21M) | (120.54M) | (1.06M) |
Beam Therapeutics Inc.
NASDAQ:BEAM
Intrinsic Alpha fair value
Locked
Current Price
$21.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.